Literature DB >> 24170241

Continuous adenosine A2A receptor antagonism after focal cerebral ischemia in spontaneously hypertensive rats.

Ulrike Fronz1, Alexander Deten, Frank Baumann, Alexander Kranz, Sarah Weidlich, Wolfgang Härtig, Karen Nieber, Johannes Boltze, Daniel-Christoph Wagner.   

Abstract

Antagonism of the adenosine A2A receptor (A2AR) has been shown to elicit substantial neuroprotective properties when given immediately after cerebral ischemia. We asked whether the continuous application of a selective A2AR antagonist within a clinically relevant time window will be a feasible and effective approach to treat focal cerebral ischemia. To answer this question, we subjected 20 male spontaneously hypertensive rats to permanent middle cerebral artery occlusion and randomized them equally to a verum and a control group. Two hours after stroke onset, the animals received a subcutaneous implantation of an osmotic minipump filled with 5 mg kg(-1) day(-1) 8-(3-chlorostyryl) caffeine (CSC) or vehicle solution. The serum level of CSC was measured twice a day for three consecutive days. The infarct volume was determined at days 1 and 3 using magnetic resonance imaging. We found the serum level of CSC showing a bell-shaped curve with its maximum at 36 h. The infarct volume was not affected by continuous CSC treatment. These results suggest that delayed and continuous CSC application was not sufficient to treat acute ischemic stroke, potentially due to unfavorable hepatic elimination and metabolization of the pharmaceutical.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24170241     DOI: 10.1007/s00210-013-0931-7

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  33 in total

1.  Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration.

Authors:  L C Schmued; K J Hopkins
Journal:  Brain Res       Date:  2000-08-25       Impact factor: 3.252

2.  Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists.

Authors:  P A Jones; R A Smith; T W Stone
Journal:  Neuroscience       Date:  1998-07       Impact factor: 3.590

3.  Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes.

Authors:  Roberta Brambilla; Lorenzo Cottini; Marta Fumagalli; Stefania Ceruti; Maria P Abbracchio
Journal:  Glia       Date:  2003-08       Impact factor: 7.452

4.  Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury.

Authors:  Liqun Yu; Zhihong Huang; Juliana Mariani; Yumei Wang; Michael Moskowitz; Jiang-Fan Chen
Journal:  Nat Med       Date:  2004-09-26       Impact factor: 53.440

Review 5.  Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat.

Authors:  Marta Kot; Władysława A Daniel
Journal:  Pharmacol Rep       Date:  2008 Nov-Dec       Impact factor: 3.024

6.  The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil.

Authors:  J W Phillis
Journal:  Brain Res       Date:  1995-12-24       Impact factor: 3.252

7.  Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.

Authors:  C L Denlinger; K K Stryker; L B Slusher; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

8.  NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.

Authors:  Hans-Christoph Diener; Kennedy R Lees; Patrick Lyden; Jim Grotta; Antoni Davalos; Stephen M Davis; Ashfaq Shuaib; Tim Ashwood; Warren Wasiewski; Vivian Alderfer; Hans-Goran Hårdemark; Larry Rodichok
Journal:  Stroke       Date:  2008-03-27       Impact factor: 7.914

9.  In vivo and ex vivo effects of adenosine A1 and A2 receptor agonists on platelet aggregation in the rabbit.

Authors:  D Sandoli; P J Chiu; M Chintala; S Dionisotti; E Ongini
Journal:  Eur J Pharmacol       Date:  1994-06-23       Impact factor: 4.432

10.  Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

Authors:  Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

View more
  4 in total

Review 1.  Caffeine and cardiovascular diseases: critical review of current research.

Authors:  Anthony Zulli; Renee M Smith; Peter Kubatka; Jan Novak; Yoshio Uehara; Hayley Loftus; Tawar Qaradakhi; Miroslav Pohanka; Nazarii Kobyliak; Angela Zagatina; Jan Klimas; Alan Hayes; Giampiero La Rocca; Miroslav Soucek; Peter Kruzliak
Journal:  Eur J Nutr       Date:  2016-03-01       Impact factor: 5.614

Review 2.  Caffeine and Its Neuroprotective Role in Ischemic Events: A Mechanism Dependent on Adenosine Receptors.

Authors:  R Brito; K C Calaza; D Pereira-Figueiredo; A A Nascimento; M C Cunha-Rodrigues
Journal:  Cell Mol Neurobiol       Date:  2021-03-17       Impact factor: 5.046

Review 3.  Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia.

Authors:  Felicita Pedata; Anna Maria Pugliese; Elisabetta Coppi; Ilaria Dettori; Giovanna Maraula; Lucrezia Cellai; Alessia Melani
Journal:  Mediators Inflamm       Date:  2014-08-05       Impact factor: 4.711

Review 4.  In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease.

Authors:  Anna Vuorimaa; Eero Rissanen; Laura Airas
Journal:  Contrast Media Mol Imaging       Date:  2017-11-20       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.